Third Edition of Tommy Hilfiger Fashion Frontier Challenge Highlights Six Global Entrepreneurs Accelerating Change in the Fashion Industry
13.12.2021 17:30:00 EET | Business Wire | Press release
Tommy Hilfiger, which is owned by PVH Corp. [NYSE: PVH], is pleased to announce the six finalists of the 2021 Tommy Hilfiger Fashion Frontier Challenge, who were carefully selected from over 430 applications received from startups and scaleups globally. Building on Tommy Hilfiger’s sustainability vision to Waste Nothing and Welcome All, the third edition of the program strives to continue amplifying and supporting black, indigenous and people of color (BIPOC) entrepreneurs who are working to advance their communities, while fostering a more inclusive future of fashion. With the need to drive impact in the industry more important than ever, the third year of the Tommy Hilfiger Fashion Frontier Challenge was done completely virtual to overcome the ongoing restrictions and challenges of the COVID-19 pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211213005214/en/
Over a multi-step year-long process, applications were thoroughly reviewed by internal and external experts based on a dedicated set of criteria including potential social impact and market growth. The six finalists will pitch their business ideas to a jury panel consisting of business and sustainability leaders at the virtual global Tommy Hilfiger Fashion Frontier Challenge final event on January 12-13, 2022.
“The Tommy Hilfiger Fashion Frontier Challenge embodies our long-standing mission to harness the power of fashion to foster inclusivity, representation and change,” said Tommy Hilfiger. “Our industry will only move forward with new, fresh ideas that challenge how we think, build and create. As a brand, it’s vital we use our platform to give entrepreneurs like our finalists a voice and opportunity to create real and long-lasting impact.”
The six finalists are:
- Clothes to Good: A South African-based social enterprise that creates micro-business opportunities and jobs for people with disabilities and their families, especially mothers, through textile recycling.
- Haelixa: A Switzerland-based product traceability technology that aims to accelerate the global transition to transparent consumer goods supply chains.
- MAFI MAFI: An Ethiopia-based sustainable fashion brand that crafts ready-to-wear collections, preserving ancient traditions and empowering marginalized artisans.
- Lalaland: A Netherlands-based platform that uses artificial intelligence to generate customized and inclusive synthetic models of different ethnicities, ages and sizes, all with over 35 pose variations.
- SOKO: This Kenya-based jewelry business uses mobile technology to connect marginalized Kenyan artisans directly to the global marketplace via a mobile platform.
- UZURI K&Y: This Rwandan-based eco-friendly shoe brand uses recycled car tires from sub-Saharan Africa and employs local youth, equipping them with skills and economic independence.
The jurors overseeing the final event are:
- Mr. Tommy Hilfiger
- Martijn Hagman, CEO, Tommy Hilfiger Global and PVH Europe
- Yara Shahidi, award-winning actress, producer, and change agent.
- Esther Verburg, EVP, Sustainable Business and Innovation, Tommy Hilfiger Global and PVH Europe
- Adrian Johnson, Entrepreneur, Adjunct Professor of Entrepreneurship, Technology and Media at INSEAD
- Katrin Ley, Managing Director of Fashion for Good and Founding Curator of the Amsterdam Global Shapers Hub
- Yvonne Bajela, founding member and principal at investment firm Impact X Capital
With the support of Tommy Hilfiger and INSEAD subject matter experts, the six finalists have developed and refined their business plans, which they will present at the final event. Arooj Aftab, content creator, illustrator, writer and founder of #DonewithDiversity, will host the final event where the jury will award €200,000 to be split between two chosen winners in order to support their ventures. The winners will also receive a year-long mentorship with both Tommy Hilfiger and INSEAD experts, as well as a place in the INSEAD Social Entrepreneurship Program (ISEP). An additional €15,000 will be awarded to the finalist who Tommy Hilfiger associates select as their 'Audience Favorite' vote.
“As key players in the fashion industry, it is our responsibility to support, empower and encourage inclusivity. The Tommy Hilfiger Fashion Frontier Challenge is a testament of our commitment to make a meaningful and lasting contribution towards a better fashion industry,” said Martijn Hagman, CEO, Tommy Hilfiger Global and PVH Europe. “It is in our nature to drive change, even in the most challenging of times. We are proud to continue amplifying the ideas of entrepreneurs that are creating the fashion landscape we want, and need, to see.”
Tommy Hilfiger’s mission is to become a leading sustainable designer lifestyle company that Wastes Nothing and Welcomes All, through how it creates its product, manages its operations and connects with its communities and stakeholders. More information about Tommy Hilfiger’s sustainability journey, which is powered by PVH’s Forward Fashion strategy, can be found on https://global.tommy.com/en_int/about-us-corporate-responsibility.
More information about the Tommy Hilfiger Fashion Frontier Challenge is available here: https://responsibility.pvh.com/tommy/fashion-frontier-challenge/. Friends and followers of the brand are invited to join the conversation on social media using #TommyHilfiger and @TommyHilfiger.
About Tommy Hilfiger
With a brand portfolio that includes TOMMY HILFIGER and TOMMY JEANS, Tommy Hilfiger is one of the world’s most recognized premium designer lifestyle groups. Its focus is designing and marketing high-quality men’s tailored clothing and sportswear, women’s collection apparel and sportswear, kidswear, denim collections, underwear (including robes, sleepwear and loungewear), footwear and accessories. Through select licensees, Tommy Hilfiger offers complementary lifestyle products such as eyewear, watches, fragrance, swimwear, socks, small leather goods, home goods and luggage. The TOMMY JEANS product line consists of jeanswear and footwear for men and women, accessories, and fragrance. Merchandise under the TOMMY HILFIGER and TOMMY JEANS brands is available to consumers worldwide through an extensive network of TOMMY HILFIGER and TOMMY JEANS retail stores, leading specialty and department stores, select online retailers, and at tommy.com.
About PVH Corp.
PVH is one of the world’s largest and most admired fashion companies, connecting with consumers in over 40 countries. Our global iconic brands include Calvin Klein and TOMMY HILFIGER . Our 140-year history is built on the strength of our brands, our team and our commitment to drive fashion forward for good. That's the Power of Us. That’s the Power of PVH.
Follow us on Facebook , Instagram, Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213005214/en/
Contact information
Tommy Hilfiger Media
Virginia Ritchie
Vice President, Global Communications
E-mail: virginia.ritchie@tommy.com
Tel: +31 6 4318 4870
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release
Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release
Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release
Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
